Portal de Periódicos da CAPES

Autoimmune Skin Rashes Associated with Etanercept for Rheumatoid Arthritis

1999; American College of Physicians; Volume: 131; Issue: 8 Linguagem: Inglês

10.7326/0003-4819-131-8-199910190-00031

1539-3704

Paul H. Brion, Anuja Mittalhenkle, Kenneth Kalunian,

Toxin Mechanisms and Immunotoxins

Letters19 October 1999Autoimmune Skin Rashes Associated with Etanercept for Rheumatoid ArthritisPaul H. Brion, MD, Anuja Mittal-Henkle, MD, and Kenneth C. Kalunian, MDPaul H. Brion, MDUniversity of California, Los Angeles; Los Angeles, CA 90095 (Brion)University of California, Los Angeles; Los Angeles, CA 90095 (Mittal-Henkle)University of California, Los Angeles; Los Angeles, CA 90095 (Kalunian), Anuja Mittal-Henkle, MDUniversity of California, Los Angeles; Los Angeles, CA 90095 (Brion)University of California, Los Angeles; Los Angeles, CA 90095 (Mittal-Henkle)University of California, Los Angeles; Los Angeles, CA 90095 (Kalunian), and Kenneth C. Kalunian, MDUniversity of California, Los Angeles; Los Angeles, CA 90095 (Brion)University of California, Los Angeles; Los Angeles, CA 90095 (Mittal-Henkle)University of California, Los Angeles; Los Angeles, CA 90095 (Kalunian)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-8-199910190-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:By targeting specific cytokines, new biological agents can suppress inflammation in autoimmune disorders with potentially fewer long-term side effects than corticosteroids and conventional antirheumatic agents. Etanercept, a soluble tumor necrosis factor receptor-fusion protein, was recently approved by the Food and Drug Administration for use in rheumatoid arthritis. We report the development of discoid lupus and necrotizing vasculitis in patients with rheumatoid arthritis who were receiving etanercept therapy.Patient 1 was a 78-year-old woman with erosive rheumatoid arthritis whose disease was uncontrolled with methotrexate and who could tolerate the addition of cyclosporine. Methotrexate and cyclosporine therapies were discontinued, ... Author, Article, and Disclosure InformationAffiliations: University of California, Los Angeles; Los Angeles, CA 90095 (Brion)University of California, Los Angeles; Los Angeles, CA 90095 (Mittal-Henkle)University of California, Los Angeles; Los Angeles, CA 90095 (Kalunian) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDrug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritisWound, pressure ulcer and burn guidelines – 4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcersSimultaneous development of cutaneous vasculitis and an autoimmune bullous skin disease during anti-TNF therapy for rheumatoid arthritis: a case report and review of the literatureThe wound/burn guidelines - 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitisEtanerceptTwo Cases of Rheumatoid Nodules Developing on the Fingers in Patients with Rheumatoid ArthritisBiologics in dermatology: adverse effectsChimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and SafetyEtanercept-induced injection site reactions: potential pathomechanisms and clinical assessmentBroad range of adverse cutaneous eruptions in patients on TNF-alpha antagonistsA case of cellulitis causing tissue defect during etanercept therapyAnti-tumor necrosis factor-α therapies for immune-mediated and inflammatory skin diseasesDrug-Induced DiseaseDrug Allergy: An Updated Practice ParameterDrug-induced subacute cutaneous lupus erythematosusDrug ReactionsCalciphylaxis in a Hemodialysis Patient on Corticosteroids and Etanercept for Psoriatic ArthritisImmunotoxicology of BiopharmaceuticsCYTOKINES AND CYTOKINE MODULATORSGLUCOCORTICOIDS AND DISEASE – MODIFYING ANTIRHEUMATIC DRUGSCutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical reviewAnaphylactic Reaction to Anakinra in a Rheumatoid Arthritis Patient Intolerant to Multiple Nonbiologic and Biologic Disease-Modifying Antirheumatic DrugsVasculitis induced by tumor necrosis factor-targeted therapiesDrug-Induced Arthritic and Connective Tissue DisordersEtanercept-Induced Lupus Erythematosus Presenting as a Unilateral Pleural EffusionDrug Insight: autoimmune effects of medications—what's new?Autoimmune Diseases Induced by TNF-Targeted TherapiesLesiones cutáneas asociadas al tratamiento anti-factor de necrosis tumoral alfaUrticaria and angiedema-like skin reactions in a patient treated with adalimumabPerforating folliculitis associated with tumour necrosis factor-? inhibitors administered for rheumatoid arthritisAutoimmunphänomene unter Therapie mit BiologicsPsoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximabHenoch-Schönlein Purpura After Etanercept Therapy for PsoriasisPsoriasis occurring during anti-TNF-α therapy: causal effect or unrelated?Characterization of an anaphylactoid reaction to omalizumabCutaneous lymphocytic vasculitis during TNFα antagonist therapy for polyarthritisVascularite cutanée lymphocytique au cours d'une polyarthrite traitée par anti-TNF-αCutaneous lupus erythematosus: A personal approach to managementAnti-TNFα therapy in rheumatoid arthritis and autoimmunityEtanerceptMusculoskeletal manifestations and autoimmune diseases related to new biologic agentsSafety of Etanercept in PsoriasisEtanerceptAggravation d'un lupus érythémateux subaigu sous infliximabCutaneous lupus erythematosus induced by infliximabCutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the LiteratureTNF?? Inhibitors in the Treatment of Psoriasis and Psoriatic ArthritisVascularite cutanée et glomérulonéphrite chez une polyarthrite rhumatoïde (PR) traitée par anti-TNFα (étanercept)Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNFα agent etanercept for rheumatoid arthritisA comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabEtanercept - review of efficacy and safety after five years of clinical useEtanercept – review of efficacy and safety after five years of clinical usePsoriatic lesions induced by antitumour necrosis factor-alpha treatment: two casesSkin reaction to adalimumabInfectious and Healing Complications after Elective Orthopaedic Foot and Ankle Surgery during Tumor Necrosis Factor-Alpha Inhibition TherapyDiscoid lupus erythematosus-like eruption induced by infliximabDRUG AND ENVIRONMENTAL LUPUS: CLINICAL MANIFESTATIONS AND DIFFERENCESManagement of Autoimmune Skin Disorders in the ElderlyCurrent Concepts in the Therapy of the SpondyloarthritidesAdverse reactions to and safety of newer disease-modifying antirheumatic drugs for rheumatoid arthritisEtanercept-induced systemic lupus erythematosusAutoimmune aspects of cytokine and anticytokine therapiesSkin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodiesSafety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritisModalités actuelles de la prise en charge thérapeutique des arthrites juvéniles idiopathiquesInfection complications associated with the use of biologic agentsNuevas perspectivas en fármacos anti-TNF-α en el tratamiento de enfermedades inflamatoriasBiologic therapies in the vasculitidesDevelopments in the Immunotherapy of Glomerular DiseaseEtanercept: Dosing, Monitoring and Side EffectsLung Injury Linked to Etanercept TherapyNew therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodiesAccelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritisRheumatoid arthritis: developing pharmacological therapiesEtanercept: A New Drug for the Treatment of Psoriatic ArthritisDrug-induced systemic lupus erythematosus associated with etanercept therapyDermatological complications of etanercept therapy for rheumatoid arthritisCutaneous and Systemic Manifestations of Drug-Induced VasculitisSafety and Efficacy of Disease-Modifying Anti-Rheumatic AgentsEtanercept‐induced subacute cutaneous lupus erythematosusTARGETING TUMOUR NECROSIS FACTOR ALPHANew drug therapies for the pediatric rheumatic diseasesRational Use of New and Existing Disease-Modifying Agents in Rheumatoid ArthritisJoel M. Kremer, MDDrugs acting on the immune systemTNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanerceptLupus induit par l'étanercept, deux observationsDevelopment of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritisEtanerceptBiologic Therapies for Inflammatory Disease 19 October 1999Volume 131, Issue 8Page: 634KeywordsAntibodiesBiopsyDNAEosinophilsLesionsMethotrexateRashesRheumatoid arthritisTumor necrosis factorVasculitis Issue Published: 19 October 1999 CopyrightCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...